A systematic review of 43 randomized controlled trials found high-certainty evidence that multiple CGRP-targeted therapies reduced monthly migraine headache days by approximately 2 days versus placebo in adults with chronic migraine.

Accelerometer-derived sleep-wake cycle metrics independently predicted incident dementia in 53,448 UK Biobank participants, with predictive improvement comparable to APOE genotype contribution when added to age-only models.

Survey responses from 5,797 Fox Insight participants suggest sleep disturbances, autonomic dysfunction, and emotional changes preceded Parkinson’s disease diagnosis by more than a decade in a substantial proportion of respondents.

The LRRK2 inhibitor BIIB122 failed to slow disease progression versus placebo in 648 early-stage idiopathic Parkinson’s patients in the Phase 2b LUMA trial, leading Biogen and Denali to discontinue joint development.

County-level analysis of nearly 5 million Medicare beneficiaries identified more than 10-fold geographic variation in late-onset epilepsy incidence, with insufficient sleep, heat index, and lack of vehicle access among the strongest area-level predictors.

Brain-predicted age difference and socioeconomic status moderated the relationship between AD pathology markers and cognitive performance in a cross-sectional cohort of 621 cognitively unimpaired older adults.